Synergistic effect of FOXM1 and BCL-2 inhibition in a preclinical treatment study on multiple myeloma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Synergistic effect of FOXM1 and BCL-2 inhibition in a preclinical treatment study on multiple myeloma ; volume:22 ; number:1 ; day:8 ; month:7 ; year:2024 ; pages:1-4 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (8.7.2024), 1-4, 12.2024
- Creator
-
Zhou, Vivian
Yu, Manya
Fu, Jiaqi
Janz, Siegfried
Cui, Xing
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-024-05452-9
- URN
-
urn:nbn:de:101:1-2409252141203.682861672249
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhou, Vivian
- Yu, Manya
- Fu, Jiaqi
- Janz, Siegfried
- Cui, Xing
- SpringerLink (Online service)
Other Objects (12)
FOXM1 regulates glycolysis and energy production in multiple myeloma
Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
BCL-2 inhibition mitigates pouchitis in a preclinical rat model
ABL1-mediated phosphorylation promotes FOXM1-related tumorigenicity by Increasing FOXM1 stability
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
Honokiol is a FOXM1 antagonist
KIAA1429 increases FOXM1 expression through YTHDF1–mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma
Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma
FOXM1 regulates glycolysis and energy production in multiple myeloma
Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
BCL-2 inhibition mitigates pouchitis in a preclinical rat model
ABL1-mediated phosphorylation promotes FOXM1-related tumorigenicity by Increasing FOXM1 stability
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
Honokiol is a FOXM1 antagonist
KIAA1429 increases FOXM1 expression through YTHDF1–mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma
Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma
FOXM1 regulates glycolysis and energy production in multiple myeloma
Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
BCL-2 inhibition mitigates pouchitis in a preclinical rat model
ABL1-mediated phosphorylation promotes FOXM1-related tumorigenicity by Increasing FOXM1 stability
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
Honokiol is a FOXM1 antagonist
KIAA1429 increases FOXM1 expression through YTHDF1–mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma
Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas